Disease · MONDO_0006032

cystitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cystitis. Diseases, record MONDO_0006032. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006032

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cystitis; Open Targets
Open Targets ID: MONDO_0006032; Open Targets
Other names: bladder infection, inflammation of urinary bladder, urinary bladder inflammation; Open Targets
Disease Ontology: DOID:1679; Disease Ontology
MeSH: D003556; MeSH
NCI Thesaurus: C26738; NCI Thesaurus
Highest stage of its drugs: Approval, for 13 of its 21 drugs, from DailyMed, PMDA and TTD; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NITROFURANTOIN	CHEMBL572	Small molecule	Approval	DailyMed	31	4	4	Drugs and targets
CIPROFLOXACIN	CHEMBL8	Small molecule	Approval	DailyMed	5	2	2	Drugs and targets
CIPROFLOXACIN HYDROCHLORIDE	CHEMBL1202	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
TAZOBACTAM	CHEMBL404	Small molecule	Approval	PMDA	2	0	0	Drugs and targets
ALCOHOL	CHEMBL545	Small molecule	Approval	TTD	1	0	0	Drugs and targets
AVIBACTAM SODIUM	CHEMBL2107817	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
CEFTAZIDIME	CHEMBL44354	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
CEFTOLOZANE SULFATE	CHEMBL1213250	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
DIMETHYL SULFOXIDE	CHEMBL504	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PIPERACILLIN	CHEMBL702	Small molecule	Approval	PMDA	1	0	0	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Investigational new drug	https://conductscience.org/library/genes/2280

Source Drugs and targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04187144	Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)	Phase 3	1,606	2023-07-18	Urinary Tract Infections	GEPOTIDACIN, NITROFURANTOIN	Its record names the disease	ClinicalTrials.gov
NCT00194532	Cefpodoxime vs Ciprofloxacin for Acute Cystitis	Not applicable	300	2011-04-28	Urinary Tract Infection	CEFPODOXIME, CIPROFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT03425396	Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis	Phase 2	225	2020-06-04	Uncomplicated Urinary Tract Infection, Cystitis	NITROFURANTOIN, OMADACYCLINE	Its record names the disease	ClinicalTrials.gov
NCT03568942	Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)	Phase 2	22	2020-01-07	Infections, Bacterial	GEPOTIDACIN	Its record names the disease	ClinicalTrials.gov
NCT01406275	Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)		363		Otitis Maedia	AMOXICILLIN, CLAVULANIC ACID	Its record names the disease	ClinicalTrials.gov
NCT06907199	Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections	Phase 1	104		Recurrent UTIs, Cystitis Recurrent	NITROFURANTOIN	Its record names the disease	ClinicalTrials.gov
NCT02555059	Special Drug Use Investigation of Ciproxan Injection in Pediatrics		48		Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax	CIPROFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT05254808	EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care	Phase 3	13		Urinary Tract Infections	FOSFOMYCIN, NITROFURANTOIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Gepotidacin vs Nitrofurantoin: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	285 of 804	200 of 798	1,602	NCT04187144	Trial comparisons
Gepotidacin vs Nitrofurantoin: Number of Participants With Serious Adverse Events (SAEs)	5 of 804	5 of 798	1,602	NCT04187144	Trial comparisons
Gepotidacin vs Nitrofurantoin: deaths from any cause	0 of 804	0 of 798	1,602	NCT04187144	Trial comparisons
Gepotidacin vs Nitrofurantoin: serious adverse events	5 of 804	5 of 798	1,602	NCT04187144	Trial comparisons
Ciprofloxacin vs Cefpodoxime: serious adverse events	0 of 150	0 of 150	300	NCT00194532	Trial comparisons

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22318279	RESULT	1	PubMed
42682990	DERIVED	1	PubMed
41495938	DERIVED	1	PubMed
41399629	DERIVED	1	PubMed
41240688	DERIVED	1	PubMed
40924012	DERIVED	1	PubMed
40924001	DERIVED	1	PubMed
40372095	DERIVED	1	PubMed
38342126	DERIVED	1	PubMed
36271314	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006032

GET https://conductscience.org/api/diseases/v1/MONDO_0006032/drugs?page=2

API reference For AI assistants